Rheumatology Enrollment Form

Ph: 806-324-5447 • Toll Free 866-629-6779
Toll Free Fax: 866-217-8034
Email: specialty@maxor.com
www.maxorspecialty.com

PATIENT INFORMATION

Patient Name ______
Date of Birth ______ ◯ Male ◯ Female
Street Address ______ Apt # ______
City ______ State ______ Zip ______
Phone-Primary ______ Secondary ______
◯ English ◯ Spanish ◯ Other ______
Email Address ______
Social Security # ______
◯ NKDA Known Drug Allergies ______
Weight ______ kg/lb Height ______ in/cm

Please attach front and back of patient's insurance cards

PHYSICIAN INFORMATION

Physician Name ______
NPI ______ License # ______
Office Contact ______
Street Address ______ Ste # ______
City ______ State ______ Zip ______
Phone ______ Fax ______

By signing this form, I authorize Maxor Specialty to act as my agent for prior authorizations & prescription reimbursement for the above listed patient.

Physician Signature ______
Date ______
◯ Dispense as written ◯ Product substitution permitted

** For Ohio patients, please only choose one (1) prescription/form.**

CLINICAL INFORMATION

Diagnosis: ◯ M06.9 Rheumatoid Arthritis ◯ L40.50 Psoriatic Arthritis ◯ M45.9 Ankylosing Spondylitis
◯ M32.10 Systemic Lupus Erythematosus ◯ L40.8 Psoriasis Moderate to Severe Plaque ◯ M81.0 Osteoporosis
◯ Other ______

Prior (FAILED): Medications ______ Length of Treatment ______ Reason for Discontinuing ______
Medications ______ Length of Treatment ______ Reason for Discontinuing ______

TB Test: ◯ Yes ◯ No Results: ______ Forteo/Prolia: T-Score: ______ Type______ Date______

PRESCRIPTION INFORMATION

CHECK TO ENROLL IN PATIENT ASSISTANCE PROGRAM ◯

MEDICATION	STRENGTH	DIRECTIONS	QTY	REFILLS
◯ **Actemra®**	◯ 4mg/kg ◯ 8mg/kg ◯ 162mg/0.9ml PFS	◯ Infuse IV over 1 hr every 4 wks ◯ <100kg inject 162mg SQ every other wk, then increase to every wk based on clinical response ◯ ≥100kg inject 162kg SQ every wk		
◯ **Benlysta®**	◯ 10mg/kg	◯ Infuse_____mg at wks 0, 2, and 4, then every 4 wks thereafter		
◯ **Cimzia®**	◯ Cimzia Starter Kit ◯ 200mg/1ml PFS (2)	**Initial Dose:** ◯ Inject 400mg SQ at wks 0,2,4 **Maintenance Dose:** ◯ Inject 200mg every other wk ◯ Inject 400mg SQ every 4 wks		
◯ **Cosentyx®**	◯ 2 pk (2X150mg)Pen/PFS ◯ 150mg (single) ◯ Pen ◯ PFS	**Initial Dose:** ◯ Inject 150mg SQ at wks 0, 1, 2, 3, 4 ◯ Inject 300mg SQ at wks 0, 1, 2, 3, 4 **Maintenance Dose:** ◯ Inject ◯ 150mg SQ every 4 wks ◯ Inject ◯ 300mg SQ every 4 wks		
◯ **Enbrel®**	◯ 50mg/ml Sureclick ◯ 50mg/ml PFS ◯ 25mg/0.5ml PFS ◯ 25mg Vial	◯ Inject 50mg SQ once a wk ◯ Inject 25mg SQ twice a wk (72-96 hrs apart) ◯ Other ______		
◯ **Humira®**	◯ 40mg ◯ Pen ◯ PFS	◯ Inject 40mg SQ every other wk ◯ Other ______		
◯ **Orencia®**	◯ 125mg PFS ◯ 250mg Vial	◯ Inject 125mg SQ once a wk ◯ >100kg: 1000mg IV wks 0, 2, 4, then Q 4 wks starting wk 8 ◯ 60 - 100kg: 750mg IV wks 0, 2, 4, then Q 4 wks starting wk 8 ◯ < 60kg: 500mg IV wks 0, 2, 4, then Q 4 wks staring wk 8		
◯ **Otezla®**	◯ Starter Pack ◯ 30mg Tablet	◯ Take 1 Tablet on day 1 then twice daily as directed ◯ Take 1 tablet by mouth twice a day		
◯ **Remicade®**	◯ 100mg Vial	◯ Infuse ________mg/kg at wks 0, 2, and 6, then ________ wks thereafter		
◯ **Rituxan®**	◯ 500mg Vial	◯ Infuse 1000mg IV days 1 and 15, then _____ wks (no sooner than 16 wks)		
◯ **Simponi®**	◯ 2mg/kg ◯ 50mg	◯ Infuse IV over 30 min, repeat dose in 4 wks, then every 8 wks thereafter ◯ Inject 50mg SQ monthly		
◯ **Stelera®**	◯ 45mg ◯ 90mg	**Initial Dose:** ◯ 45mg SQ; repeat dose in 4 wks ◯ >100kg (220lbs) and with plaque psoriasis 90mg SQ; repeat dose in 4 wks **Maintenance Dose:** ◯ 45mg Q 12 wks starting at 16 wks ◯ >100kg(220lbs) and with plaque psoriasis 90mg Q 12 wks starting at 16 wks		
◯ **Xeljanz®**	◯ 5mg Tablet ◯ 11mg XR Tablet	◯ Take 5mg by mouth twice a day ◯ Take 11mg by mouth once a day		
◯ **Other**				

Date meds needed: ______ ◯ New ◯ Refill
Ship to: ◯ Patient's home ◯ Physician's Office ◯ Other ______

CONFIDENTIALITY NOTICE: This communication is intended for and should be delivered to the individual or entity to which it is addressed and contains information that is privileged, confidential and exempt from disclosure under applicable law. If you are not the named addressee, you should not disseminate, distribute or copy this information. Please notify the sender immediately if you have received this document in error.

2016 Maxor NPS LLC All Rights Reserved